Dianthus Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 1.2, 1.46, 12.74, 240.57, 717.28 ], "ebit_estimate": [ -219.62, -277.3, -313.21, -205.58, 173.04 ], "ebitda_estimate": [ null, null, null, null, null ], "net_income_estimate": [ -196.62, -256.49, -294.13, -188.49, 110.89 ], "per_share_eps_estimate": [ -3.78, -4.54, -5.11, -3.31, 2.21 ], "eps_nri_estimate": [ -3.74, -4.51, -5.11, -3.31, 1.25 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -199.12, -258.92, -292.99, -170.11, 237.92 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 60.49, 90, 88, 88, 85 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 44.1 ], "long_term_growth_rate_mean": -8.06, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -8.03, "future_eps_nri_estimate_growth": -8.06, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -21.28, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -22.74, "future_pretax_income_estimate_growth": -22.56, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 0.26, 0.27, 0.26, null, null, null, null ], "ebit_estimate": [ -51.12, -57.05, -65.99, -61.15, -61.97, -65.13, -78.54 ], "ebitda_estimate": [ null, null, null, null, null, null, null ], "net_income_estimate": [ -45.14, -51.34, -60.38, -54.12, -55.13, -58.42, -71.97 ], "per_share_eps_estimate": [ -0.88, -0.99, -1.13, -1, -1.01, -1.05, -1.21 ], "eps_nri_estimate": [ -0.86, -0.97, -1.12, -1, -1.01, -1.05, -1.21 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -45.82, -51.96, -61.06, -54.12, -55.13, -58.42, -71.97 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 49.6, 49.56, 49.51, 100, 100, 100, 100 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -8.06, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -8.03, "future_eps_nri_estimate_growth": -8.06, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -21.28, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -22.74, "future_pretax_income_estimate_growth": -22.56, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }